To determine the clinical activity and safety of the combination of pemetrexed and gemcitabine in advanced nonclear cell renal cell carcinoma (nccRCC).
R enal cell carcinoma (RCC) represents approximately 90% of all kidney cancer cases. Approximately 58,240 cases of kidney cancer were diagnosed in 2010 in the United States, with approximately 13,040 deaths due to metastatic disease. 1 Eighty-five percent of RCC are clear cell (conventional) type, with the remaining nonclear cell tumors comprised papillary types 1 and 2, chromophobe, collecting duct, renal medullary carcinoma, translocation, unclassified RCC, and other more rare types. The current standard of care for the systemic treatment of metastatic renal cell carcinoma (mRCC) is targeted therapy with antivascular endothelial growth factor agents and mammalian target of rapamycin (mTOR) inhibitors. [2] [3] [4] [5] [6] However, the majority of the patients in the pivotal trials that led to the approval of these targeted agents had clear cell (conventional) RCC. Temsirolimus, compared with interferon-a, demonstrated improved overall survival (OS) in patients with mRCC of any histologic subtype and poor-risk features. However, there is no established effective therapy for good-risk and intermediaterisk nonclear cell mRCC, hence the need to explore new therapeutic approaches for this group of diverse diseases.
Single-agent cytotoxic chemotherapy and combinations of cytotoxic agents have been extensively studied in mRCC. In the pretargeted therapy era, a phase II study of infusional fluorouracil in mRCC showed a 5% response rate and median survival of 12 months. Gemcitabine is a pyrimidine antimetabolite that demonstrated response rates of 6% and 8% in 2 phase II trials. [7] [8] [9] A phase II study of infusional 5-FU with weekly gemcitabine showed an objective response rate (ORR) of 17% and median progression-free survival (PFS) of 28.7 weeks. 10 The combination of gemcitabine and capecitabine has been studied in patients with mRCC in 4 single-arm phase II trials, with response rates ranging from 8% to 16%, stable disease rates ranging from 48% to 67%, and median PFS ranging from 4.6 to 7.6 months. [11] [12] [13] [14] Pemetrexed is a broad-spectrum antifolate antineoplastic agent. It inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, with preclinical activity against RCC cell lines and a partial response rate of 9% in 1 phase II clinical trial. 15, 16 The combination of pemetrexed and gemcitabine was tested in multiple phase II and III trials in advanced non-small cell lung cancer, breast cancer, bladder cancer, and pancreatic cancer. [17] [18] [19] [20] Here, we report the results of a phase II trial of the combination of pemetrexed and gemcitabine in patients with metastatic nonclear cell renal cell carcinoma (nccRCC).
PATIENTS AND METHODS
This is a single-arm phase II trial with Simon 2-stage design 21 in patients with nonclear cell mRCC. The primary objective of this trial was to assess the efficacy of the combination of pemetrexed and gemcitabine. The primary endpoint was based on ORR and PFS. The secondary endpoints were safety and OS. Target enrollment was 40 patients. On the basis of the Bayesian probability modeling, the trial would be discontinued, if there were a >70% probability that the PFS rate at 16 weeks was <25%. An ad hoc composite decision rule for assessing futility was planned after 20 patients were enrolled, with termination of the trial if fewer than 2 patients of 20 patients had a partial response.
Patients were eligible for the study, if they were 18 years or older and had confirmed locally advanced or metastatic nccRCC. Patients were required to have radiographically measurable disease, an Eastern Cooperative Oncology Group performance status of 0 to 2, life expectancy of at least 8 weeks, and no prior chemotherapy. Patients who received up to 2 prior targeted therapies or had surgical resection or prior radiation therapy for brain metastasis were not excluded. Patients had to have adequate organ and bone marrow functions. This was defined as hemoglobin Z9 g/dL, absolute neutrophil count of Z1500/mL, platelets Z100,000/mL, serum total bilirubin r1.5 mg/dL, serum aspartate aminotransferase and alanine aminotransferase r2.5 times the upper limit of normal, and creatinine clearance of Z45 mL/min (by the Cockcroft-Gault method). Exclusion criteria included pregnancy or lactation and prior malignancies unless treated and disease free for 2 years or nonmelanoma skin cancer. Written informed consent was obtained before enrolment for all patients. The trial was approved by the Institutional Review Board. Both pemetrexed and gemcitabine were supplied by Lilly and Co.
Before treatment, evaluation consisted of a complete medical history, physical exam, laboratory testing as described, chest x-ray, computed tomography scans of the chest/ abdomen/pelvis, and a computed tomography or magnetic resonance imaging scan of the brain.
Therapy consisted of pemetrexed 500 mg/m 2 intravenous (IV) infusion over 10 minutes on day 1 followed immediately by gemcitabine 1500 mg/m 2 IV over 30 minutes on day 1, repeated every 14 days. Folic acid, 350 to 1000 mcg orally daily, was administered 5 to 7 days before the first dose of pemetrexed and continued throughout therapy and for 21 days after the last dose of pemetrexed. Vitamin B12 1000 mcg was given intramuscularly 1 week before first dose of pemetrexed and every 8 to 9 weeks during therapy. Complete blood counts with differential and platelet counts were obtained weekly. Liver function tests and complete chemistry profiles were obtained every 2 weeks. A minimum absolute neutrophil count of 1500Â10 6 /L and a minimum platelet count of 100 Â10 9 /mL were required before each cycle of therapy was administered. Radiographic studies were repeated every 8 weeks (or 4 cycles of treatment) or as needed to confirm response or progression.
All patients were evaluated for response by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. 22 Toxicity was assessed using the National Cancer Institute-Common Toxicity Criteria version 3.0. Dose reductions by 25% of the initial dosing for both gemcitabine and pemetrexed were used for grade 3 or 4 nonhematologic toxicity, neutropenic fever requiring hospitalization, grade 4 thrombocytopenia, or a treatment delay of >7 days for any toxicity. Up to 3 dose reductions were allowed. Dose reductions of 50% for both agents were used for grade 3 or 4 mucositis.
The ORR was evaluated with 95% confidence intervals (CI). The median PFS, 16-week PFS rate, and median OS were estimated with 95% CIs using the Kaplan-Meier product method. PFS was defined as the time from the date of registration to the date of documentation of disease progression, patient withdrawal, or death. OS was defined as the time from the date of registration to the date of last follow-up or death.
RESULTS
Between December 2005 and December 2008, 16 patients were enrolled in this study. One patient withdrew consent and did not receive treatment. One patient received treatment with pemetrexed and gemcitabine but was subsequently found to have urothelial cell carcinoma of the renal pelvis at the time of nephrectomy. Thus, 14 patients were included in the efficacy analysis and 15 patients were included in the toxicity analysis. The patients' characteristics are shown in Table 1 . Among the 14 patients, 5 patients discontinued treatment before the first response assessment: 4 because of toxicity and 1 by patient choice. Under the intention-to-treat principle, all eligible enrolled patients were included in the primary analysis. The median number of cycles administered was 4 (range, 1 to 12). Four patients (29%) received 8 or more cycles of chemotherapy. Five patients (36%) discontinued therapy due to unacceptable toxicity. Eight patients (57%) received pemetrexed and gemcitabine in the first-line setting; 3 patients (21%) and 2 patients (14%) received the combination in the second-line and third-line settings, respectively. Six patients (42%) received alternative systemic therapy after they were taken off protocol ( Table 2) .
The ORR among all 14 patients was 0%. Waterfall plot of best tumor responses for the 12 patients who completed restaging imaging is shown in Figure 1 ; the only patient with a partial tumor response by REICIST criteria was found to have urothelial carcinoma at nephrectomy. Median PFS was 3.2 months (95% CI, 1.9-6 +) (Fig. 2) . The 16-week PFS rate was 46.7% (95% CI, 19.8%-100%). Median OS was 23.2 months (95% CI, 12.9-38.1) (Fig. 3) .
The safety data are summarized in Table 3 . All of the 15 patients who received protocol treatment were evaluable for toxicity. Thirteen patients (87%) experienced grade 3 or 4 adverse events, and 7 patients (47%) experienced grade 4 toxicity. The most common grade 3 or 4 adverse events were neutropenia (53%), leukopenia (53%), and fatigue (40%). One patient developed pulmonary embolism and had therapy discontinued. There were no deaths on therapy due to toxicity, and there were no cases of neutropenic fever.
DISCUSSION
In this phase II study, gemcitabine and pemetrexed were administered to patients with locally advanced and metastatic, nccRCC, to assess the efficacy and safety in this patient population. The combination of gemcitabine and pemetrexed had not been previously studied in mRCC. The current standard of care for the treatment of mRCC is antivascular endothelial growth factor therapy or mTOR inhibitors. The tyrosine-kinase inhibitors, sorafenib, sunitinib, and pazopanib, and the humanized antibody, bevacizumab, in combination with interferon-a, were approved for the treatment of advanced disease. 2, 3, 6 Everolimus, an oral mTOR inhibitor, was approved for mRCC, after tyrosine-kinase inhibitor failure. 4, 5 The phase III trials that led to the approval of these targeted agents enrolled patients with RCC who had a major clear cell component. Temsirolimus is the only approved agent that was studied in clear cell and nccRCC. 23 The treatment of advanced nccRCC has been evaluated in several retrospective and phase II trials to date. In a retrospective study, 64 patients with advanced nccRCC treated with cytokine therapy had a median OS of 9.4 months. 24 Another retrospective study of 53 patients with mRCC, who were treated with targeted therapy (sunitinib or sorafenib), showed median PFS of 7.6 months for papillary RCC and 10.6 months for chromophobe RCC. 25 A phase II trial of erlotinib in patients with papillary mRCC yielded an 11% response rate and median OS of 27 months. 26 Two phase II trials of sunitinib in advanced nccRCC produced median PFS of 5.6 and 2.7 months, respectively, much lower than reported in clear cell RCC. 27, 28 RCC has traditionally been viewed as resistant to cytotoxic chemotherapy. 29 However, multiple phase I and II studies showed modest activity against this disease with singleagent 5-FU, capecitabine, or gemcitabine, with ORRs ranging from 5% to 8%. The combination of gemcitabine and capecitabine or infusional 5-FU has shown improved response rates, with occasional durable responses. 12, 13, 30 A retrospective study of 28 patients with mRCC (35% nonclear cell histology) treated with the combination of gemcitabine, capecitabine, and bevacizumab showed a median PFS of 6.2 months and a median OS of 11.7 months. 31 In this trial, we chose to combine pemetrexed, a multienzyme-inhibiting antimetabolite, and gemcitabine in an attempt to improve upon the activity of fluoropyrimidine/gemcitabine combinations.
Pemetrexed was approved for first-line and second-line treatment of locally advanced or metastatic nonsquamous nonsmall cell lung cancer and malignant pleural mesothelioma, in combination with a platinum agent. [32] [33] [34] [35] The combination of gemcitabine and pemetrexed was studied in a phase II trial of patients with locally advanced bladder cancer, yielding a response rate of 28% and grade 3 or 4 toxicities including neutropenia (38%), febrile neutropenia (17%), sepsis (3%), anemia (19%), and thrombocytopenia (9%). In this study, gemcitabine 1250 mg/m 2 was administered IV over 30 minutes on days 1 and 8 with pemetrexed 500 mg/m 2 administered on day 1 of a 21-day cycle. 19 A phase II trial in patients with advanced nonsmall cell lung cancer used a 14-day schedule of pemetrexed 500 mg/m 2 and gemcitabine 1500 mg/m 2 administered on day 1. The response rate was 26%, and the most common grade 3 or 4 toxicities were neutropenia (47%), leukopenia (25%), fatigue (25%), and anemia (8%). 17 Another phase II trial of this combination in patients with metastatic breast cancer showed a similar response rate but required a protocol amendment due to excessive toxicities (71% grade 3 or 4 neutropenia) in the planned 21-day administration cycle. The most common toxicities in the amended 14-day cycle group were neutropenia (32.7%), leukopenia (13.5%), and anemia/ thrombocytopenia (9.5%). A phase III trial of gemcitabine and pemetrexed versus gemcitabine in patients with locally advanced pancreatic cancer on a 21-day schedule showed a similar toxicity profile. 20 A phase II trial of pemetrexed in 39 patients with mRCC showed a partial response rate of 9% and median time to progression of 10.5 months. 16 In this study cohort, we observed an ORR of 0% by RECIST criteria. Two patients had tumor shrinkage <30% as their best response; 1 patient with collecting duct carcinoma (26% reduction) and 1 patient with papillary RCC (14% reduction). Seven patients (50%) had progressive disease as their best response. Median PFS was 3.2 months (95% CI, 1.9-6 +) for the entire cohort. Median OS was 23.2 months; however, many patients received salvage therapies after disease progression with pemetrexed and gemcitabine. The study was term inated early based on lack of clinical benefit and unacceptable toxicity. The toxicity profile in this patient cohort was more formidable than that reported in studies with this combination in other tumor types. The excessive toxicity observed in our study may be partly explained by compromised renal function in some RCC patients, compared with patients with other tumor types.
CONCLUSIONS
In this small phase II trial, the chemotherapy regimen of pemetrexed plus gemcitabine was toxic and ineffective in patients with locally advanced or metastatic nccRCC. Further investigation of this chemotherapy combination in nccRCC is not warranted. Enrollment of patients with advanced nccRCC on clinical trials should be a priority, as there is as of yet no established effective therapy other than temsirolimus. Probability of Progression Free (7) Nonhematologic toxicities Fatigue 6 (40) Renal failure 2 (13) Hyperglycemia 1 (7) Nausea 1 (7) Vomiting 1 (7) Constipation 1 (7) ALT, SGPT 1 (7) AST, SGOT 1 (7) Pulmonary embolism 1 (7) Non-neutropenic fever 1 (7) 
